

CardioComm Solutions Inc. Receives Enthusiastic Response at Annual Heart Rhythm Society Meeting

VICTORIA, B.C., May 22, 2007 – CardioComm Solutions Inc. (TSX-V:CCG) ("CardioComm", the "Company"), is pleased to advise shareholders that the Company was well received at the Annual Heart Rhythm Society meeting held in Denver last week.

Throughout the meeting, CardioComm discussed the next phase of its GEMST[™] software due for release in late Q2 2007. This release will include an updated version of its Health Level 7 (HL7) module which will be available for purchase by existing and new customers. HL7 has become the recognized standard for data exchange and messaging between software systems, enabling systems to exchange and synchronize patient data in multiple systems. This improves both the quality data, and reduces repetitive data entry.

CardioComm has been consulted by several device manufacturers to assist in developing state of the art devices that are well integrated into the Company's software solutions. Most recently, CardioComm has begun development on receiving digital files and wireless transmissions from event monitors.

CardioComm client base now exceeds 450 customers worldwide using its cardiac event monitoring software. This includes cardiac monitoring services, hospitals, clinics, and small practices. CardioComm has become recognized by the industry as a leader in Cardiac event monitoring software.

About CardioComm Solutions Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMST[™]) and GlobalCardio[™]. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions Inc.

"Stephen Martin"

Stephen R. Martin, President & CEO

For investor information, please contact:

Stephen Martin

1-877-744-1122

ir@cardiocomm.com

*The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release*